Building a true strategy about your pharmaceutical drugability
Years of experience
Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Back to the images of the 2023 AFSSI Connexions in Montpellier (4th and 5th of July)... The old medicine faculty of Montpellier held for 2 days the 2023 AFSSI Connexions. In between plenary sessions...